Journal
INTERNATIONAL JOURNAL OF NANOMEDICINE
Volume 15, Issue -, Pages 5767-5781Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S254574
Keywords
mammalian target of rapamycin; cancer; rapalogs; mTOR kinase inhibitor; RapaLinks; nanotechnology; nanoparticles
Funding
- National Research Foundation (NRF) of Korea - Korean government (Ministry of Science and ICT) [NRF-2018R1A2B6004513]
- Gachon University [GCU 2018-0312]
Ask authors/readers for more resources
Mammalian target of rapamycin (mTOR) is a master regulator of cell growth and metabolism, which is activated in response to intra- and extracellular signals, including nutrients, growth factors, and cellular energy levels. The frequent dysregulation of mTOR signaling in cancer makes it an attractive therapeutic target, and several types of mTOR inhibitors have been developed. Nanoparticle-based mTOR modulators are predicted to target various cancers and deliver as well as release drugs in a controlled manner, resulting in enhanced bioavailability and reduced side effects. This mini-review is focused on the molecular mechanism of nanoparticle-based mTOR modulator action as well as the current development of mTOR inhibitors using nanoparticles. Understanding the biological function of nanoparticle-based mTOR modulators will contribute to the development of efficient nano-therapeutics for the treatment of cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available